SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 07:53:28 2024-07-11 am EDT | ||
| 23.75 EUR | -0.67% |
|
| Current month | -0.91% | ||
| 1 month | +9.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 23.75 | -0.67% |
| 24-07-10 | 23.91 | +0.42% |
| 24-07-09 | 23.81 | -0.92% |
| 24-07-08 | 24.03 | +0.08% |
| 24-07-05 | 24.01 | -1.11% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 07:53 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VX0B11 |
| ISIN | DE000VX0B112 |
| Date issued | 2021-08-06 |
| Strike | 3,556 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 11.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.98 € |
|---|---|
| Lowest since issue | 3.47 € |
| Spread | 0.02 € |
| Spread % | 0.08% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,765
DKK
Average target price
2,446
DKK
Spread / Average Target
+38.60%
- Stock Market
- Certificates
- Certificat
